ArticleCancer control : journal of the Moffitt Cancer Center
M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLC.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of clinical, pathological and genomic characteristics between Lynch and non-Lynch patients with MMRd endometrial carcinoma.BMC cancer · 2026Article
- Hsa_circ_0003176: a key player in the m6A modification-mediated regulation of autophagy and glycolysis in cisplatin-resistant non-small cell lung cancer.Human cell · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionNon-small cell lung cancer (NSCLC), which accounts for >85% of all lung cancers, is the most common solid malignant tumor, with high morbidity and mortality worldwide. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment is widely used clinically because the epidermal growth factor receptor (EGFR) is the main driver gene of lung cancer; however, the development of drug resistance is inevitable. Epigenetic abnormalities can also lead to tyrosine kinase inhibitor (TKI) resistance. However, the relationship between N6-methyladenosine (m6A)-related proteins and EGFR mutations in NSCLC and their clinical significance remain unclear. In this retrospective study, the expression of m6A-related regulatory factors in patients with EGFR mutations were analyzed to investigate their relationship with clinicopathological features and prognoses.MethodsThe association between m6A-related regulatory factors and NSCLC was analyzed using data derived from The Cancer Genome Atlas, case collection, follow-up, immunohistochemistry, and scoring.ResultsA total of 246 NSCLC specimens were examined in this study. Among these, 143 EGFR-mutant cases exhibited significantly higher expression of METTL3 and ALKBH5 compared to EGFR-wildtype specimens. The median progression-free survival time of patients with high METTL3 expression (SI >6) was 25.0 months, and that of patients with high ALKBH5 expression (SI >6) was 24.1 months in EGFR-mutant cases. High METTL3 and ALKBH5 expression levels are independent risk factors for progression-free survival in patients with EGFR mutations. The median progression-free survival time of patients with EGFR mutations was 45.7 months in those with high expression of METTL3 or ALKBH5 alone, whereas it decreased to 20.1 months in those with high simultaneous expression of METTL3 and ALKBH5.ConclusionsMETTL3 and ALKBH5 were upregulated in NSCLC tissues with EGFR mutations and significantly correlated with poor prognoses. Thus, METTL3 and ALKBH5 may serve as prognostic biomarkers in EGFR-mutant NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.